Literature DB >> 18673212

Beta-secretase: structure, function, and evolution.

Chitra Venugopal1, Christina M Demos, K S Jagannatha Rao, Miguel A Pappolla, Kumar Sambamurti.   

Abstract

The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (Abeta), which is generated by cleavage of the Abeta protein precursor (APP) by beta-secretase (BACE-1) followed by gamma-secretase. BACE-1 cleavage is limiting for the production of Abeta, making it a particularly good drug target for the generation of inhibitors that lower Abeta. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Abeta generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673212      PMCID: PMC2921875          DOI: 10.2174/187152708784936626

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  205 in total

1.  Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP.

Authors:  A Kamal; A Almenar-Queralt; J F LeBlanc; E A Roberts; L S Goldstein
Journal:  Nature       Date:  2001-12-06       Impact factor: 49.962

2.  Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch.

Authors:  Y Gu; H Misonou; T Sato; N Dohmae; K Takio; Y Ihara
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

3.  PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease.

Authors:  Bart Dermaut; Esther A Croes; Rosa Rademakers; Marleen Van den Broeck; Marc Cruts; Albert Hofman; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Ann Neurol       Date:  2003-03       Impact factor: 10.422

4.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

5.  Evolutionary fate of duplicate genes encoding aspartic proteinases. Nothepsin case study.

Authors:  Lucia Borrelli; Roberta De Stasio; Silvana Filosa; Elio Parisi; Marilisa Riggio; Rosaria Scudiero; Francesca Trinchella
Journal:  Gene       Date:  2006-01-10       Impact factor: 3.688

6.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

7.  Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides.

Authors:  Krystyn Z Bourne; Diana C Ferrari; Christine Lange-Dohna; Steffen Rossner; Thomas G Wood; J Regino Perez-Polo
Journal:  J Neurosci Res       Date:  2007-05-01       Impact factor: 4.164

8.  Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties.

Authors:  M Haniu; P Denis; Y Young; E A Mendiaz; J Fuller; J O Hui; B D Bennett; S Kahn; S Ross; T Burgess; V Katta; G Rogers; R Vassar; M Citron
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

9.  In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

Authors:  Sethu Sankaranarayanan; Eric A Price; Guoxin Wu; Ming-Chih Crouthamel; Xiao-Ping Shi; Katherine Tugusheva; Keala X Tyler; Jason Kahana; Joan Ellis; Lixia Jin; Thomas Steele; Shawn Stachel; Craig Coburn; Adam J Simon
Journal:  J Pharmacol Exp Ther       Date:  2007-12-21       Impact factor: 4.030

10.  Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.

Authors:  B Pillon; B Deweer; Y Agid; B Dubois
Journal:  Arch Neurol       Date:  1993-04
View more
  33 in total

Review 1.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

2.  Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Ghulam M Ashraf; Nigel H Greig; Taqi A Khan; Iftekhar Hassan; Shams Tabrez; Shazi Shakil; Ishfaq A Sheikh; Syed K Zaidi; Mohammad Akram; Nasimudeen R Jabir; Chelaprom K Firoz; Aabgeena Naeem; Ibrahim M Alhazza; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 3.  Regulation of the alternative β-secretase meprin β by ADAM-mediated shedding.

Authors:  Franka Scharfenberg; Fred Armbrust; Liana Marengo; Claus Pietrzik; Christoph Becker-Pauly
Journal:  Cell Mol Life Sci       Date:  2019-06-14       Impact factor: 9.261

4.  Anti-amyloidgenic and neurotrophic effects of tetrahydroxystilbene glucoside on a chronic mitochondrial dysfunction rat model induced by sodium azide.

Authors:  Ru-Yi Zhang; Lan Zhang; Li Zhang; Yu-Lan Wang; Lin Li
Journal:  J Nat Med       Date:  2018-03-05       Impact factor: 2.343

5.  Coupling enhanced sampling of the apo-receptor with template-based ligand conformers selection: performance in pose prediction in the D3R Grand Challenge 4.

Authors:  Andrea Basciu; Panagiotis I Koukos; Giuliano Malloci; Alexandre M J J Bonvin; Attilio V Vargiu
Journal:  J Comput Aided Mol Des       Date:  2019-11-13       Impact factor: 3.686

6.  Computational Evaluation of Interaction Between Curcumin Derivatives and Amyloid-β Monomers and Fibrils: Relevance to Alzheimer's Disease.

Authors:  Adrian Orjuela; Johant Lakey-Beitia; Randy Mojica-Flores; Muralidhar L Hegde; Isaias Lans; Jorge Alí-Torres; K S Rao
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 7.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 8.  Recent Progress in the Pharmacotherapy of Alzheimer's Disease.

Authors:  Rita Khoury; Kush Patel; Jake Gold; Stephanie Hinds; George T Grossberg
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

Review 9.  Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.

Authors:  Johant Lakey-Beitia; Ruben Berrocal; K S Rao; Armando A Durant
Journal:  Mol Neurobiol       Date:  2014-05-15       Impact factor: 5.590

10.  New drug discovery for Alzheimer's disease: Challenges and hopes.

Authors:  T S Sathyanarayana Rao; K Jagannatha Rao
Journal:  Indian J Psychiatry       Date:  2009-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.